Zoetis continues to focus on developing new products and extending the lifecycle of existing products through new claims, formulations, and combinations. This strategy aims to maximize the value of their portfolio.

The company completed acquisitions of PetMedix and adivo in 2023, and Jurox and Basepaws in 2022, which are intended to enhance their portfolio and capabilities in companion animal and livestock products, as well as petcare genetics.

Zoetis continues to establish a direct presence in emerging markets, with 21% of total revenue coming from these markets. This reflects a strategic focus on global expansion and growth opportunities.

Zoetis emphasizes workplace culture, diversity, equity, and inclusion, and talent development. The company's engagement rate remains high at 86% in 2023, reflecting a positive work environment.

The company intends to continue efficiency improvement programs, including Six Sigma and Lean capabilities, to enhance manufacturing efficiency and maintain quality standards.

Zoetis prioritizes R&D spending and investments in digital solutions and data insights to drive future growth and improve customer experience.

The animal health industry is highly competitive, with increased consolidation and generic competition, which could lead to price pressures and reduced market share for Zoetis. Generic versions of Rimadyl and Draxxin have already impacted sales.

The company's revenue is heavily reliant on a few top-selling products and product lines, such as Simparica/Simparica Trio and Apoquel/Apoquel Chewable, making them vulnerable to issues such as patent loss, competition, and regulatory changes.

Macroeconomic, business, political, and financial disruptions, including public health crises and geopolitical instability, could have a material adverse effect on Zoetis' operations and financial condition.

Zoetis is the largest company by revenue in the animal health industry, which provides a competitive advantage in terms of scale and market reach.

The company offers a diverse product portfolio for both companion animals and livestock, allowing it to capitalize on various market trends and customer needs.

Zoetis faces increasing competition from generic products and lower-cost alternatives, which could negatively impact its pricing power and market share.

Zoetis continues to implement efficiency improvement programs, including Six Sigma and Lean capabilities, to enhance manufacturing and supply chain operations.

The company operates a global manufacturing network of 29 sites and utilizes 109 third-party contract manufacturing organizations (CMOs) to support its production needs.

The company's manufacturing and supply chain are subject to various risks, including deviations in processes, equipment malfunctions, shortages of materials, and labor problems, which could lead to production interruptions and increased costs.

Zoetis invested $614 million in R&D in 2023, reflecting its commitment to developing new products and solutions. This is an increase from $539 million in 2022 and $508 million in 2021.

The company is investing in digital solutions and data analytics to enhance its business and improve customer experience, highlighting its focus on technological advancements.

A significant portion of R&D investment is focused on product lifecycle innovation, including expanding claims, formulations, and combinations, as well as expanding usage into more countries.

The company has a multi-year share repurchase program of up to $3.5 billion, with $1.5 billion remaining as of December 31, 2023, indicating a focus on returning value to shareholders.

Zoetis has completed several acquisitions, including PetMedix, adivo, Jurox, and Basepaws, indicating a strategy of investing in growth opportunities and expanding its product offerings.

The company is investing in capital expenditures to improve its manufacturing capabilities and support its R&D efforts, reflecting a commitment to long-term growth.

Zoetis has a sustainability program called Driven to Care, which includes various ESG aspirations and goals. The company is committed to being a responsible corporate citizen.

The company is committed to creating a diverse and inclusive workplace, with specific aspirations to increase the representation of women and underrepresented groups.

Zoetis has implemented comprehensive health and safety programs and standards, with a focus on injury prevention and a best-in-class safety culture.

The animal health market is growing due to factors such as increasing pet ownership, economic development, and increased demand for animal protein. Zoetis is well-positioned to benefit from this growth.

Zoetis is subject to various regulations in different countries, and changes to these regulations could impact its business. The company actively engages in dialogue with global agencies.

The company is exposed to global economic and political risks, including public health crises, geopolitical instability, and trade restrictions, which could negatively impact its business.